Service area · GDP logistics

Temperature control & last mile: 2–8 °C and 15–25 °C

From goods receipt to patient handover, every temperature-relevant medicine needs a product-, pack- and route-specific quality concept. Blanket temperature promises never replace a qualified supply chain.

Review temperature control and last-mile model →
Temperature mapping and control in pharmaceutical logistics

GDP · temperature control · last mile

Temperature mapping and control in pharmaceutical logistics

From goods receipt to patient handover, every temperature-relevant medicine needs a product-, pack- and route-specific quality concept. Blanket temperature promises never replace a qualified supply chain.

tiger.PHARMA designs and reviews temperature control for storage, B2B transport and B2C delivery: with defensible product data, packaging and route qualification, controlled carrier performance and documented decisions for deviations and returns.

tiger.PHARMA Expertise

Topics we master

Temperature mapping for warehouses and routes

Temperature mapping for warehouses and routes

Risk determines protocol, season, load, hot and cold spots, sensor positions, acceptance criteria and requalification.

  • 15–25 °C and 2–8 °C GDP mapping
  • Summer, winter and worst case
  • Calibrated loggers and sensor positions
  • DQ, IQ, OQ and PQ
  • Requalification after change
Assess temperature excursions

Assess temperature excursions

Affected stock is quarantined and evaluated using product, time, route, packaging and stability evidence.

  • Alarm and quarantine
  • Data and product assessment
  • Release or rejection decision
  • Root cause and CAPA
Product profile, storage zones & data

Product profile, storage zones & data

The starting point is not a generic cold label but the approved product information and stability evidence that is reliable for the particular supply chain.

  • Align product and PZN data with manufacturer and release information
  • Map and qualify warehouse temperature zones
  • Define data ownership, version control and review cadence
  • Do not assign a generic corridor without documented evidence
Packaging matrix & route qualification

Packaging matrix & route qualification

Packaging, transit time and route are assessed as one configuration, including season, handover point and realistic delay scenarios.

  • Product-, pack- and route-specific packaging matrix
  • Passive or active solution only within a qualified configuration
  • Document climate-chamber, duration and stress scenarios
  • Define fallback, blocking or replanning when conditions are not met
Carrier SLA & validated last mile

Carrier SLA & validated last mile

The last mile is not determined by shipping method alone. Medicine, patient group, delivery location, handover and carrier performance form one risk profile.

  • Choose carriers by product, geography and delivery risk
  • SLA for lead time, deviation notification and escalation
  • Identity, personal or contact-light handover according to risk
  • Use KPIs, proof of delivery and partner reviews for ongoing control
Monitoring, calibration & evidence

Monitoring, calibration & evidence

Measurement should be meaningful, not decorative. Sensors, indicators and data loggers are selected according to the risk assessment and controlled by quality processes.

  • Measurement concept by product, route and pack configuration
  • Maintenance, calibration and functional-check concept
  • Traceable data retention, access rights and records
  • Data-minimised communication with patients and recipients
Deviation, return & quality decision

Deviation, return & quality decision

A temperature deviation or returned parcel is a quality case: secure first, assess second, then let the responsible role make a traceable decision.

  • Block or quarantine pending quality assessment
  • Assess time, route, measurements, packaging and product requirements together
  • Document release, rejection or further investigation
  • Use MKT only where product-specific stability data and written decision logic support it
B2B, B2C & cross-border supply chains

B2B, B2C & cross-border supply chains

Warehouse and wholesale processes and direct patient delivery need different controls, but can be managed through one shared quality picture.

  • Qualified warehouse, transport and outsourcing interfaces
  • Separate rules for B2B handovers and B2C patient supply
  • Review destination market, mandatory information and reporting before go-live
  • Connect quality agreements, training and CAPA
Turn quality findings into storage and transport actions

Turn quality findings into storage and transport actions

If the assessment calls for changes to goods flows or providers, plan storage and transport together. Define handovers, data, partners and deviation controls in an operational work package. Quality findings and Responsible Person responsibilities inform that scope.

    FAQ

    Frequently asked questions

    Does the same temperature apply to every medicine?

    No. The approved product information, defensible stability data and the qualified packaging and route configuration are decisive. A general temperature assumption does not replace a product-specific assessment.

    How is a last mile qualified for temperature-sensitive medicines?

    By combining the product profile, packaging, route, season, delivery model, carrier performance and documented delay scenarios. The configuration is assessed before routine use and monitored according to risk.

    What happens after a temperature deviation?

    The parcel or return is secured or blocked. Measurements, time, route, packaging and product requirements are assessed, then the responsible quality role documents release, rejection or further action.

    Can MKT automatically release a returned parcel?

    No. MKT can only be used as supportive evidence when product-specific stability data, a qualified measurement concept and a written quality decision permit it.

    How is pharmaceutical storage at 15–25 °C qualified?

    Qualification combines representative summer and winter temperature mapping, calibrated sensors, defined alarm limits, deviation procedures and risk-based requalification. Product-specific storage conditions remain decisive.

    What matters for medicines stored at 2–8 °C?

    Storage, packaging, routes, hubs, transit time, monitoring and contingencies must be qualified as one cold chain. Excursions require a documented product-specific quality decision.